Immunophage Biomedical Co. Ltd. has synthesized macrophage migration inhibitory factor (MIF) inhibitors reported to be useful for the treatment of cancer and inflammation.
Exelixis Inc. has disclosed membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Gluetacs Therapeutics (Shanghai) Co. Ltd. has synthesized oxoisoindolinyl substituted piperidinedione derivative molecular glue degraders characterized as IKZF1, IKZF3 and GSPT1 degradation inducers. They are reported to be useful for the treatment of cancer, anemia, liver failure, diabetes, infections, sarcoidosis, autoimmune diseases and cardiovascular disorders.
An Iongen Therapeutics Co. Ltd. patent reports transient receptor potential vanilloid 3 (TRPV3) receptor antagonists that are potentially useful for the treatment of acne, diabetes, anxiety, gastrointestinal, inflammatory and respiratory disorders, neurodegeneration and obesity, among others.
Jiangsu Vcare Pharmatech Co. Ltd. has created new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to estrogen receptor α (ER-α)-binding moiety through a linker. They are reported to be useful for the treatment of cancer and infections.
Acrivon Therapeutics Inc. has identified new pyrimidine carboxamide compounds acting as Wee1-like protein kinase (Wee1) inhibitors potentially useful for the treatment of cancer.
Enanta Pharmaceuticals Inc. has patented compounds acting as nonstructural protein 3 (nsp3, PL-pro; SARS-CoV-2) inhibitors reported to be useful for the treatment of asthma, SARS-CoV-2 infection (COVID-19), rhinovirus, norovirus and lung infections.
As the U.S. Congress continues to pass laws that require federal agencies to issue rules to implement new statutory provisions, a group of lawmakers is reminding the agencies that it will be looking over their shoulders to ensure they don’t stray beyond the scope of the law or overstep their authority.
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has described oxime-containing compounds acting as stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of psoriasis, rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes, multiple sclerosis, inflammatory bowel disease, transplant rejection and neurodegeneration, among others.
Researchers at Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM) and Université Côte d'Azur have divulged amidinourea derivatives reported to be useful for the treatment of cancer, in particular for BRAF inhibitor-resistant melanoma.
RSS
